Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD). "The completion of the Alzheimer’s study marks a significant step in our efforts to bring new therapies to patients,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “The study progressed as intended with minimal dropout rate." A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled. "The team is now fully focused on meticulously cleaning and analyzing the data, aiming to deliver results in a timely manner," said Melissa Gaines, Senior Vice President, Clinical Operations. About the Phase II/III TrialThe phase II/III study is a randomized, double-blind, placebo-control
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders [Yahoo! Finance]Yahoo! Finance
- Annovis Bio CEO Maria Maccecchini Issues Letter to StockholdersGlobeNewswire
- Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market [Seeking Alpha]Seeking Alpha
- Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects [Seeking Alpha]Seeking Alpha
- Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question [Seeking Alpha]Seeking Alpha
ANVS
Earnings
- 8/14/23 - Beat
ANVS
Sec Filings
- 5/2/24 - Form 8-K
- 5/1/24 - Form 8-K
- 5/1/24 - Form 424B5
- ANVS's page on the SEC website